





PHARMACEUTICAL 2022

MADRIGAL PHARMACEUTICALS INC. Rank 455 of 475



The relative strengths and weaknesses of MADRIGAL PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MADRIGAL PHARMACEUTICALS INC. compared to the market average is the variable Selling, General and Administrative Expense, increasing the Economic Capital Ratio by 132% points. The greatest weakness of MADRIGAL PHARMACEUTICALS INC. is the variable Net Income, reducing the Economic Capital Ratio by 547% points.

The company's Economic Capital Ratio, given in the ranking table, is -912%, being 636% points below the market average of -276%.

| Input Variable | Value in 1000 USD |
|---|-------------------|
| Assets, Current | 271,684 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 0 |
| Liabilities, Current | 76,838 |
| Liabilities, Non-Current | 387 |
| Other Assets | 797 |
| Other Compr. Net Income | -127 |
| Other Expenses | 205,164 |
| Other Liabilities | 0 |
| Other Net Income | 363 |
| Property and Equipment | 851 |
| Research and Development | 205,164 |
| Revenues | 273 |
| Selling, General and Administrative Expense | 37,318 |

| Output Variable | Value in 1000 USD |
|--------------------------|-------------------|
| Assets | 273,332 |
| Liabilities | 77,225 |
| Expenses | 447,646 |
| Stockholders Equity | 196,107 |
| Net Income | -447,010 |
| Comprehensive Net Income | -447,074 |
| Economic Capital Ratio | -912% |

